Is patient-to-patient transmission of Aspergillus fumigatus in CF patients possible?
A new study from the Netherlands has challenged the widely held opinion that airborne transmission of Aspergillus fumigatus between patients with cystic fibrosis (CF) does not occur.
Chronic Pulmonary Aspergillosis (CPA) is a chronic condition affecting patients with structural lung damage such as that caused by CF. It is generally accepted that patients become colonised by A. fumigatus following the inhalation of spores from the environment.
Posaconazole works better than itraconazole and voriconazole against ABPA amongst Cystic Fibrosis patients
A recently published research paper suggests that Posaconazole works better than itraconazole and voriconazole against
allergic bronchopulmonary aspergillosis (ABPA) in patients with Cystic Fibrosis.
ABPA patients tend to have a hypersensitive response to Aspergillus species which results in inflammation, airway destruction and bronchiectasis. Cystic fibrosis (CF) patients are at risk of ABPA which then speeds up lung function decline. The current ‘gold standard’ treatment is prednisolone to reduce inflammation. Azoles have been used effectively as steroid alternatives but have various side effects and tolerance issues.
In the newly published paper the authors wanted to know if posaconazole, which is known to be less toxic and better absorbed than other azoles, was more effective at treating ABPA.
They analysed data from 596 CF patients, and reviewed the specific Aspergillus IgE levels and azole levels in blood samples. 32 patients were identified and included in the analysis. 11 had itraconazole alone, 12 had two different azoles and 9 received all three azoles. In total, 30 received itraconazole, 13 received voriconazole, 18 received posaconazole.
The authors found IgE levels to be significantly reduced when posaconazole was used, but not the other azoles, suggesting that monitoring posaconazole levels and altering the dose given to the patient to attain greater serum levels of IgE gives improved blood test results in ABPA patients.
Want to know more? Read the paper here!
Lung function tests
[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.19.1" _module_preset="default" theme_builder_area="post_content" custom_margin="3px|auto|3px|auto|true|false"][et_pb_column _builder_version="4.19.1" _module_preset="default" type="4_4" theme_builder_area="post_content"][et_pb_text _builder_version="4.19.1" _module_preset="default" theme_builder_area="post_content" hover_enabled="0" sticky_enabled="0"]
At this month’s patient support meeting Phil Langridge, Specialist Physiotherapist at Manchester University NHS Foundation Trust, Wythenshawe Hospital, gave a fantastic talk all about spirometry and lung function tests.
He started the talk with a simple question “Do you look forward to lung function tests?” An audience member offered a simple reply “No, it’s purgatory”.
Lung function tests are hard. The thing is, they’re maximum function tests. The staff carrying out the tests sometimes sound a bit strict, firmly telling you to keep going and put more effort in. The tests are tough, and for some people they can take a while to recover from. That’s because they need maximum effort and it can take a lot out of some people.
Phil gave us an overview of most commonly used tests, starting with the spirometry test. Sometimes these tests can be done at your GP surgery with a practice nurse in a familiar setting. Sometimes they have to be done in hospital and this can lack privacy and be a bit intimidating. Try not to worry, staff understand this, just tell them you’re feeling nervous and they’ll do what they can to help so your test gives the best result possible.
Spirometry is used to:
- Detect respiratory disease
- Measure bronchial responsiveness
- Diagnose and differentiate between obstructive lung disease and restrictive lung disease
- Assess impairment from occupational asthma
- Conduct pre-operative risk assessments before anaesthesia or cardiothoracic surgery
- Measure response to treatment of conditions which spirometry detects – including aspergillosis.
What do lung function numbers depend on?
Lots of factors influence lung function numbers including age, gender, race, height and weight.
You might be predicted a number that can give you a feel of where you sit in the ‘normal’ range.
But you mustn’t fixate on that number, your performance in tests can be affected by things that are nothing to worry about, for example, you might have had a rubbish night’s sleep, skipped breakfast, had to wait ages in the waiting room for you appointment, already seen the physio to get a sputum sample and THEN had to do lung function. Your performance might then be very different to another day where you walk straight into the test room having slept like a baby, had a full English and been the first person seen that day.
What do the tests measure?
FEV1. This is the forced expiatory volume in one second i.e. how much air you can empty from your lungs in the first second – this is a good measure of your airway obstruction, or how ‘floppy’ your airways are. If it’s lower than expected, you might have airway obstruction. This is an important one to measure when doing drug effectiveness tests.
FVC. This is forced vital capacity and is the test where you’re blowing your hardest and the physio is shouting ‘Keep going! Keep going! Keep going!’ and you feel like you might pass out! FVC is the amount of air you can expel from your lungs in total and so you’re encouraged to ‘keep going’ because staff have to make sure you’re giving it your best and completely emptying your lungs so that the test result is accurate and meaningful.
You might have to wear a nose clip during FVC. This is so that you don’t release air through your nose which can give a lower result. You usually have to do FVC three times and an average result is taken, the machine you blow in to plots volume exhaled against time.
Peak Flow – How fast you can exhale. This test can be helpful as a monitoring tool for asthma but isn’t used that often in clinic.
The thing with these measurements compared to e.g. blood tests or CT scans is that they’re effort dependent. It’s important to remember that for the results to be meaningful and therefore informative and useful, you really have to do the best you can.
FVC can be lowered if you have an obstructive or restrictive condition. The ratio between FVC and FEV1 gives clues as to whether you have an obstructive condition or a restrictive condition and can help to diagnose conditions such as COPD.
A healthy person will have a ratio of around 80%, i.e. when they empty their lungs, 80% of air will be expelled in the first second, but if you struggle to get the air out because of obstructed or floppy airways it takes you longer to empty them, it may be lower. If it’s 70% or less it might be COPD.
Doing this at the GP can help to diagnose without having to send people to a specialist centre with all the extra costs of travel and parking and the extra anxiety of being in an unfamiliar setting. Lots of GP surgeries now have nurses who can do spirometry to help with COPD diagnosis.
The frequency of tests can vary too, depending on your condition, what treatment you’re on, if you’re changing treatment, if you’re having survey. If you’re stable with COPD and asthma and you’re being managed by your GP, you might only have lung function tests every 5 years or so. It’s very variable.
Here’s a top tip from Phil! Ignore your lung age if you’re told it! It’s scary and meaningless!
Phil is 41 years old, he is healthy, he doesn’t have lung disease, he cycles to work and he plays for the first team at his hockey club regularly. His lung age came out at 54!
That sounds scary! If you’re told it, it might make you feel very worried. We have patients who visit our clinic who have a lung age of 150 and they’re stable and have had that value for years and years. It really doesn’t mean anything.
Why might people be told it then? Well, it might go back to persuading people to stop smoking, it might scare people into quitting smoking if they’re told they have the lungs of a 90 year old but they are only 60. But this can back fire and be quite nihilistic, people might think ‘oh well, my lungs are shot to pieces already, no point in doing anything to ty and help, I’ll just carry on as I am’. It’s not a helpful measure at all.
Some of the questions from the session:
Can you expand the lung having had a lobe removed due to an aspergilloma?
After thoracic surgery you might be put on an enhanced recovery programme. You may be given an incentive spirometer to encourage you to take slow deep breathes. Deep breathing and exercise such as brisk walking can really help with recovery from surgery too.
Do you need to worry about bleeds when you’re doing lung function tests?
Deep breathing will not cause your lungs to bleed but your clinic will always be careful if you are known to have thin walled lung cavities.
Watch Phil’s talk and let us know what you think!
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Yeast that live in the human gut can trigger the immune system to cause inflammation in the lung, especially in patients with ABPA.
The yeast Candida albicans lives in the gut as a
commensal organism, usually without issue. C. albicans causes the body
to produce a particular kind of immune cell, called Th17 sensitive cells, that
stop the Candida from causing infections. A new research paper out this
month shows that the Th17 cells that react to Candida in the gut also
react to Aspergillus in the lung by a process called ‘cross reactivity’.
Cross reactivity was shown to increase the levels of Aspergillus
reactive Th17 cells in the blood of patients with Cystic Fibrosis, COPD and
asthma, especially during ABPA. This indicates that there is a direct link
between the normal, protective Th17 responses against Candida in the
gut, and harmful inflammation by Aspergillus in the lung.
In other words, problems in your lungs might be made worse by the normal immune response to Candida in your gut. This knowledge could affect the way we treat flare ups in future. For example, we already know that using antibiotics can increase the growth of Candida in the gut. This new information raises the possibility that increased Candida in the gut could cause increased lung inflammation or a ‘flare up’ of symptoms in patients with Aspergillosis, but further work would be needed to confirm this.
Read the paper here
Awareness of lung cancer risk in people with COPD
This article was originally written for The Hippocratic Post.
Pulmonary Rehabilitation - is it worth it?
In last month’s patient meetings here at Wythenshawe Hospital, the topic of pulmonary rehabilitation (PR) came up. Some people said it had been useful, some people felt pushed into it, some people felt it was too much and actually made them feel worse instead of better.
This gave us food for thought and we went away to look at the literature. Has anyone studied the outcomes of PR from the patients’ perspective?
The answer was yes! In October last year a paper was published on exactly that, a survey of 1685 people with self-reported chronic lung disease in 29 countries.
Patient stories from World Aspergillosis Day
[et_pb_section admin_label="section"]
[et_pb_row admin_label="row"]
[et_pb_column type="4_4"][et_pb_text admin_label="Text"]
On World Aspergillosis Day (February 1st), the Aspergillosis Trust organised a whole host of activities and awareness campaigns, to mark the occasion. Alongside their very successful Selfie Campaign, and the poster that was displayed on London buses in the run up to the day, the Aspergillosis Trust collected some poignant stories from patients and carers. Click here to read these stories and find out more about what the Aspergillosis Trust does.
[/et_pb_text][/et_pb_column]
[/et_pb_row]
[/et_pb_section]
Air Pollution Worldwide - Check your town
There is now a worldwide reference point for air pollution for many pollutants that will irritate the lungs of people with lung disease.
Beautiful Cure: Harnessing your body’s natural defences
We think that people who have chronic aspergillosis may have slight differences in their immune system compared with people who do not seem to be vulnerable to aspergillosis. One way we might be able to help patients fight off aspergillosis may well be to find ways to adjust or even correct the immune differences that cause those vulnerabilities and this book talks about our increasing knowledge and power to do just that in many other diseases. The same techniques may be used to help people with respiratory illness' such as aspergillosis - indeed they already are as anyone who is being given Xolair to treat ABPA has found out.